Child pages
  • UODB - UCSF Urologic Oncology Publications

Versions Compared


  • This line was added.
  • This line was removed.
  • Formatting was changed.


97. Kornberg Z, Cooperberg MR, Cowan JE, Chan JM, Shinohara K, Simko JP, Tenggara I, Carroll PR. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology for Men on Active Surveillance. J Urol. 2019 Oct;202(4):702-709. PMID: 31026214

98. Lange JM, Laviana AA, Penson DF, Lin DW, Bill-Axelson A, Carlsson SV, Newcomb LF, Trock BJ, Carter HB, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Etzioni RB. Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts. Cancer. 2019 Oct 22. Epub ahead of print. PMID: 31639200 

99. Newcomb LF, Zheng Y, Faino AV, Bianchi-Frias D, Cooperberg MR, Brown MD, Brooks JD, Dash A, Fabrizio MD, Gleave ME, Liss M, Morgan TM, Thompson IM, Wagner AA, Carroll PR, Nelson PS, Lin DW. Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). Prostate Cancer Prostatic Dis. 2019 Sep;22(3):438-44. PMID: 30664734


100. Odisho AY, Bridge M, Webb M, Ameli N, Eapen RS, Stauf F, Cowan JE, Washington SL 3rd, Herlemann A, Carroll PR, Cooperberg MR. Automating the Capture of Structured Pathology Data for Prostate Cancer Care and Research. JCO Clin Informatics 2019 Jul;(3):1-8. PMID: 31314550


101. Shenk JM, Newcomb LF, Zheng Y, Faino AV, Zhu K, Nyame YA, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW. African American race is not associated with risk of reclassification during active surveillance: results from the Canary Prostate Cancer Active Surveillance Study (PASS). J Urol. 2019 Oct 25. Epub ahead of print. PMID: 31651227

102. Xu MJ, Kornberg Z, Gadzinski AJ, Diao D, Cowan JE, Wu SY, Boreta L, Spratt DE, Behr SC, Nguyen HG, Cooperberg MR, Davicioni E, Roach M 3rd, Hope TA, Carroll PR, Feng FY. Genomic risk predicts molecular imaging-detected metastatic nodal disease in prostate cancer. Eur Urol Oncol. 2019 Nov;2(6):685-690. PMID: 31411984


103. Zhao SG, Lehrer J, Chang SL, Das R, Erho N, Liu Y, Sjöström M, Den RB, Freedland SJ, Klein EA, Karnes RJ, Schaeffer EM, Xu M, Speers C, Nguyen PL, Ross AE, Chan JM, Cooperberg MR, Carroll PR, Davicioni E, Fong L, Spratt DE, Feng FY. The immune landscape of prostate cancer and nomination of PD-L2 as a potential therapeutic target. J Natl Cancer Inst2019 Mar 1;111(3):301-310. Epub 2018 Oct 13. PMID: 30321406


102104. Washington SL 3rd, Baskin AS, Ameli N, Nguyen HG, Westphalen AC, Shinohara K, Carroll PR. MRI-based prostate-specific antigen density predicts Gleason score upgrade in an active surveillance cohort. AJR Am J Roentgenol. 2020 Jan 8:1-5. Epub ahead of print  PMID: 31913068